A second phase Ib/II study combining IMCgp100 with merestinib in metastatic uveal melanoma

Trial Profile

A second phase Ib/II study combining IMCgp100 with merestinib in metastatic uveal melanoma

Planning
Phase of Trial: Phase I/II

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs IMC gp100 (Primary) ; Merestinib (Primary)
  • Indications Uveal melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 25 Jan 2016 According to a Immunocore media release, IMCgp100 has been granted Orphan drug designation by U.S. FDA for the treatment of uveal melanoma.
    • 09 Sep 2015 According to a Immunocore media release, IMCgp100 has been accepted to participate in the European Medicines Agency's (EMA) Adaptive Pathways (formerly Adaptive Licensing) pilot programme and plans to seek conditional approval for IMCgp100 for the treatment of patients with metastatic uveal melanoma, which will be subject to the successful completion of this study.
    • 01 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top